A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis

Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Maria Gavriatopoulou, Constantinos Pamboukas, Ioannis Boletis, Smaragda Marinaki, Theofanis Apostolou, Nikitas Nikitas, Georgios Gkortzolidis, Eurydiki Michalis, Sossana Delimpasi, Meletios A. Dimopoulos*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science